Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
  • 3

  • 2

  • 1

  • 1

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Country of Funder
Start Year
Active Year
Similar Projects for


A phase II randomised feasibility study of Chemoresection and surgicAl management in Low rIsk non muscle invasive Bladder cancER (CALIBER)

Funder: NIHR Central Commissioning Facility

Funding period
GBP 350 K
USD 576 K
Funding amount
Background Bladder cancer is the seventh most common UK cancer, with around 10,500 people diagnosed in 20091. Approximately 49% of all patients with bladder cancer have low risk NMIBC3. This recurs frequently and a patient survey indicated that inpatient surgical management of recurrence was the most bothersome aspect of the condition. CALIBER thus investigates using chemotherapy within the bladder (chemoresection) as an outpatient alternative to inpatient surgery for recurrence. Chemotherapy is routinely used following surgery to treat patients with higher risk disease4 and may enable low risk patients to avoid surgical management under general anaesthetic altogether. Primary research question In low risk recurrent NMIBC, is outpatient chemoresection a potential alternative to inpatient surgical management that is worthy of further research? Objectives To demonstrate that chemoresection will enable 60% of participants to avoid surgical intervention for low risk NMIBC recurrence, as assessed by complete response rate at 3 months. To collect further information to support development of a phase III study. Plan of investigation CALIBER is a multicentre feasibility study. 174 patients with recurrent low risk NMIBC will be randomised (2:1) over 27 months to: Chemoresection (116 patients): 4 once weekly intravesical installations of 40mg Mitomycin-C; or Surgical management (58 patients - control): type of surgery according to local practice. Participants will be followed up after treatment according to European Association of Urology guidelines4. Endpoints are: o Feasibility of recruitment o In the chemoresection group: Primary endpoint: complete response (CR) 3 months post-treatment (i.e. absence of any tumour assessed visually by patients’ urologists) Treatment compliance; o Both groups: Time to recurrence in patients disease free at 3 months; Salvage surgery rate; Progression-free survival; Toxicity; Quality of life; Working days missed; Cost effectiveness The sample size has been determined based on the assessment of CR in the chemoresection group using a Simon’s 2 stage phase II design. A control group has been included to provide prospective data about surgical management and outcomes and assess feasibility of recruitment to a randomised study. Following consultation with patient representatives, CALIBER has been designed to exclude a CR rate of less than 45%. A CR rate lower than this would suggest that chemoresection is not an attractive alternative to surgical management as it would delay rather than prevent surgical intervention in the majority of patients and hence would be unlikely to reduce the impact of treatment of recurrence. If 25 or fewer responses are seen in the first 51 chemoresection patients the trial will be stopped for futility. If at least 58/110 chemoresection patients have a CR overall then it would be concluded that the CR rate was at least 60% and thus the strategy of chemoresection would warrant further investigation Progression to phase III randomised controlled trial Should CALIBER demonstrate that response rates associated with chemoresection are at least 60%, and that recruitment is feasible in this setting, a definitive phase III trial will be developed. This will compare the effects of chemoresection versus surgical management on time to subsequent recurrence, with the aim of establishing whether chemoresection can offer patients with recurrent low risk NMIBC the opportunity to avoid surgery. Potential benefits to patients and the NHS CALIBER will identify potential benefits of chemoresection to be further explored in a phase III trial. If chemoresection is ultimately proven to be as effective as surgical management, benefits to patients should include fewer side effects and reduced impact on day to day living. In addition, chemoresection delivered to outpatients will release surgical resources currently utilised in treatment of low risk NMIBC, which could be reassigned elsewhere.

USD 11.7 M
Aggregated funding amount
USD 2.0 M
Average funding amount
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 1,313,632
2019 - 2024
Project list item
Transurethral En Bloc Versus Standard Resection of Bladder Tumour: A Multi-centre Randomised Controlled Trial (EB-StaR study).

University Grants Committee to TEOH Yuen Chun Jeremy

USD 75,486
2018 - 2020
Project list item
BladderPath: Image Directed Redesign of Bladder Cancer Treatment Pathways

NIHR Evaluation Trials and Studies Coordinating Centre to Nicholas James

USD 1,974,056
2016 - 2021
Project list item
PHOTOdynamic versus white light-guided treatment of non-muscle invasive bladder cancer: A randomised trial of clinical and cost-effectiveness (The PHOTO Trial)

NIHR Evaluation Trials and Studies Coordinating Centre to Rakesh Heer

USD 3,921,397
2014 - 2020
Project list item
Novel IL-15 Superagonist Therapy for Bladder Cancer

National Cancer Institute to HING C. WONG

USD 225,279
2011 - 2013
Project list item
Novel IL-15 Superagonist Therapy for Bladder Cancer

National Cancer Institute to JOHN LEE, HING C. WONG, PETER R RHODE

USD 4,196,403
2010 - 2020